Related Experiment Videos
Inhaled fluticasone in bronchiectasis: a 12 month study.
1Department of Respiratory and Critical Care Medicine, University Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong. kwttsang@hku.hk
Thorax
|March 3, 2005
Summary
Inhaled corticosteroids (ICS) improve sputum volume in bronchiectasis patients. This treatment is especially beneficial for those with Pseudomonas aeruginosa infection, showing improvements in sputum volume and exacerbation frequency.
Area of Science:
- Pulmonology
- Clinical Pharmacology
Background:
- Bronchiectasis is characterized by chronic airway inflammation, yet the efficacy of inhaled corticosteroids (ICS) remains unevaluated.
- The study addresses the lack of clinical data on ICS in managing bronchiectasis.
Purpose of the Study:
- To evaluate the clinical efficacy of inhaled fluticasone propionate in patients with bronchiectasis.
- To determine if ICS treatment impacts key clinical outcomes such as sputum volume, exacerbation frequency, and lung function.
Main Methods:
- A double-blind, randomized controlled trial involving 86 bronchiectasis patients.
- Patients received either fluticasone 500 mug twice daily or a placebo for 52 weeks.
- Outcomes assessed included 24-hour sputum volume, exacerbation frequency, lung function tests, and sputum purulence.
Main Results:
- ICS treatment significantly improved 24-hour sputum volume compared to placebo (p=0.03).
- Patients with Pseudomonas aeruginosa infection showed significant improvements in sputum volume (p=0.03) and exacerbation frequency (p=0.01) with ICS.
- Subgroup analyses indicated ICS benefit in patients with lower baseline sputum volume, fewer exacerbations, and higher sputum purulence scores.
Conclusions:
- Inhaled corticosteroid treatment demonstrates clinical benefit in patients with bronchiectasis.
- The positive effects are particularly pronounced in patients with concurrent Pseudomonas aeruginosa infection.